Balyasny Asset Management
CRBU icon

Balyasny Asset Management’s Caribou Biosciences CRBU Stock Holding History

Balyasny Asset Management’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-52,419
Closed -$86K – 2795
2024
Q2 		$86K Sell
52,419
-110,264
-68% -$352K ﹤0.01% 2410
2024
Q1 		$836K Buy
+162,683
New +$1M ﹤0.01% 1867
2022
Q2 		– Sell
-11,812
Closed -$108K – 2812
2022
Q1 		$108K Buy
+11,812
New +$124K ﹤0.01% 2130

Other funds holding CRBU

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Balyasny Asset Management's CRBU Position: Q3 2024 in Review

Balyasny Asset Management sold out of Caribou Biosciences (CRBU) in Q3 2024, closing a stake of 52,419 shares — an estimated $86K sold.

Balyasny Asset Management first reported a position in CRBU in Q1 2022 and held it in 3 quarters. The position peaked at $836K in Q1 2024. 129 funds tracked by Wall St. Rank hold CRBU as of Q3 2024.

  • Balyasny Asset Management reported no remaining Caribou Biosciences position as of Q3 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 52,419 Caribou Biosciences shares in Q3 2024, an estimated $86K.
  • Balyasny Asset Management first reported a position in Caribou Biosciences in Q1 2022 and held it in 3 quarters.
  • Balyasny Asset Management's Caribou Biosciences position peaked at $836K in Q1 2024.
  • 129 funds tracked by Wall St. Rank held Caribou Biosciences as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.